Patent Term Extension In Israel

Slides:



Advertisements
Similar presentations
Security of Payment workshop Andrew Robertson Important Disclaimer: The material contained in this publication is comment of a general nature only and.
Advertisements

1 Hatch-Waxman Boot Camp July 19-20, 2010 Mary C. Till Legal Advisor Office of Patent Legal Administration.
Arbitration in Poland Practical issues Monika Hartung Legal Adviser, Partner Warsaw 16 June 2011.
Management of an IR: Selected forms and procedures to encounter during the lifespan of the IR Israel, February 8, 2012 Debbie Roenning Director, Legal.
A New Pathway for Follow-on Biologics Presented by: Steve Nash May 7, 2010.
Patent Litigaton Strategies in Israel Reuven Behar, partner Fischer Behar Chen & Co.
1 Patent Term Extension under 35 U.S.C. § 156 Mary C. Till Legal Advisor Office of Patent Legal Administration.
The Life Sciences Lawyer’s Guide to PTA and PTE
Data Protection Overview
December 8, Changes to Patent Fees Under the Consolidated Appropriations Act, 2005 (H.R. 4818)(upon enactment) and 35 U.S.C. 103(c) as Amended by.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA AN OVERVIEW OF PATENT PROTECTION IN ZAMBIA.
“International distribution and marketing agreements” - Legal Aspects - © Copyright 2008 Naomi Assia & Co. – Law Offices, Patent Attorney’s and Notary.
IP Translator perceived by the legal professionals Dr. Katalin Szamosi ECTA Member Attorney at Law Managing Partner of SBGK Patent and Law Offices ECTA.
Data protection and extension of patent rights TRIPS requirements & TRIPS-plus provisions Carlos Correa.
Korean Patent Practice - Pharmaceutical field - Jonghyeok Park MS., Ph.D.course Jonghyeok Park MS., Ph.D.course Partner Pharmacist Patent Attorney.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA PROPOSED PATENT BILL AND ITS RELEVANCY.
Practical Aspects of IP Arbitration: Improving the negotiating position Olav Jaeger September 14, 2009.
Professor Peng  Patent Act (2008) ◦ Promulgated in 1984 ◦ Amended in 1992, 2000, and 2008.
Investing in research, making a difference. Patent Basics for UW Researchers Leah Haman Intellectual Property Associate WARF 1.
SIS- Schengen Information System The Office for personal data protection.
2011 Japanese Patent Law Revision AIPLA Annual Meeting October 21, 2011 Yoshi Inaba TMI Associates.
November Lovells Trademark and Design Right Enforcement in the European Union Part I France Marie-Aimée de Dampierre, Paris.
Post-Grant & Inter Partes Review Procedures Presented to AIPPI, Italy February 10, 2012 By Joerg-Uwe Szipl Griffin & Szipl, P.C.
© 2008 International Intellectual Property June 24, 2009 Class 8 Patents: Multilateral Agreements (WTO TRIPS); Global Problem of Patent Protection for.
ADAMS & ADAMS Intellectual Property within the Pharmaceutical Industry Presentation to SAPRAA. 04 September 2009 By : Alexis Apostolidis B.Sc (Chem, Law);
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA PROPOSED PATENT BILL AND ITS RELEVANCY.
Rabbanai T. Morgan Current as of 26 January 2006 Protests.
A: Copy –Rights – Artistic, Literary work, Computer software Etc. B: Related Rights – Performers, Phonogram Producers, Broadcasters etc. C: Industrial.
What is a trademark? ™.  A trademark is a word, phrase, symbol or design, or a combination thereof, that identifies and distinguishes the source of the.
‘Linkage’ & other TRIPS+ provisions: a public health perspective Karin Timmermans World Health Organization Seminar “Data exclusivity and patent Bangkok.
Biotechnology Chemical Pharmaceutical Customer Partnership
1 Patent Claim Interpretation under Art. 69 EPC – Should prosecution history be used to interpret the patent? presented at Fordham 19th Annual Conference.
CABLING SYSTEM WARRANTY REGISTRATION. PURPOSE OF CABLING REGISTRATION.
PATENTS, INTEGRATED CIRCUITS, AND INDUSTRIAL DESIGNS Presented By: Navdeep World Trade Organization.
Excellent Public Schools Act of 2013 Instructional Collaboration Day II January 3, 2014.
Intellectual Property and Public Policy: Application of Flexibilities in the International IP and Trade system --Limitation and Exceptions for Education.
PAHO has created a mechanism in order that the countries that do not have aptitude to guarantee generic insurances accede to them in an immediate.
Article 4 [Obligations of Applicant] 4.1. As a sole and exclusive owner of the Application, Applicant warrants that.
Unit 3 Seminar International Issues in IP Law. Unit 3 – International Issues in IP Law Unit 3 will focus on Chapters 8, 16 & 21 –Make sure to download.
GST TRANSITIONAL PROVISIONS
PCT-FILING SYSTEM.
INTELECTUAL PROPERTY RIGHTS
The Life Sciences Lawyer’s Guide to PTA and PTE
Consumer Protection Act, 1986
Content of Tender Dossier - Instructions to Tenderers - Tenders
Intellectual Property Protection and Access to Medicines
Agency, distributorship and franchising contracts in the United Arab Emirates IDI Annual Meeting, 13 June 2009, Barcelona
Patent law update.
WIPO NATIONAL SEMINAR ON INTELLECTUAL PROPERTY RIGHTS AND THE PROTECTION OF PHARMACEUTICAL PRODUCTS Damascus, April 25 and 26, 2005 Current issues on Intellectual.
Recognition and enforcement of foreign judgments and arbitral awards in Russia Roman Zaitsev, PhD, Partner 05/09/2018.
Biotechnology Chemical Pharmaceutical Customer Partnership
PERFORMING ANIMALS PROTECTION AMENDMENT BILL (B9-2015): AN UPDATE
Annual general meeting
SPCs and the unitary patent package
MEMORANDUM OF ASSOCIATION
Texas Secretary of State Elections Division
IMPLICATIONS OF THE CONSTITUTIONAL COURT JUDGMENT ON THE restitution of land rights amendment act on the OPERATIONS OF THE COMMISSION 7 September 2016.
CHALLENGES TO VOTER REGISTRATION APPLICATIONS AND REGISTERED VOTERS
Lawyers for Human Rights v Minister of Home Affairs and others, CCT 38/16: Judgment declaring parts of S 34 of the Immigration Act invalid and inconsistent.
Pharma Workshop IV Patent Linkage in the USA
INTELLECTUAL PROPERTY RIGHTS (IPR) IN FP7
General Data Protection Regulations 2018
Law of Intellectual Property Rights
Temporary Event Notices
What are the types of intellectual property ?
VAT Module 10 (b) VAT Administration and Compliance
THE BAILIFFS ACT, CHAPTER 4:61
LABOUR LAW TRADE UNION.
Stakeholders sensitization PRESENTED BY ANTHONY GACHAI PTA
Presentation transcript:

Patent Term Extension In Israel Sanford T. Colb & Co. Intellectual Property Law Rehovot (Main office) | Tel-Aviv | Jerusalem Patent Term Extension In Israel By David Colb, Adv & Barak Mashiah, Adv

PTE- Introduction The term Patent Term Extension (hereinafter “PTE”) refers to the extension of the protection period which is accorded to a patent relating to a medicinal preparation or substance, beyond the 20 year protection period. The principal grounds for enabling an extension of the protection period are as follows: The extended period of time needed in order to obtain marketing approval for a medicinal preparation Generic companies are, under certain conditions, permitted to carry out experimental acts during the patent period, in order to obtain a license immediately after the patent has expired, and a PTE constitutes a counter-balance to this permission.

PTE in Israel Who may apply for an extension order? The applicant for registration of a basic patent.* The owner of a basic patent. The owner of an exclusive license in a basic patent or in an application to register a basic patent. What is the deadline for filing a request for grant of PTE? An application for grant of an extension order must be submitted no later than 90 days from the registration date of the medicinal preparation, even if the patent application is still pending. *Basic patent: A patent that protects any material whatsoever. A patent that protects a process for the production of a substance. A patent that protects use of a substance. A patent that protects a medicinal preparation that incorporates a substance. A patent that protects a process for the production of a medicinal preparation that incorporates a substance. A patent that protects medical equipment that requires a license in Israel.

PTE in Israel [The Israel Patents Law] Conditions for grant of an extension order (Unofficial Translation)   The Commissioner shall not grant an extension order unless all of the following conditions have been met: The substance, the process for the production or use of the substance, or the medicinal preparation that incorporates the substance or the process for the production of the medicinal preparation, or the medical equipment, was claimed in the basic patent and the basic patent remains in effect; In respect of a medicinal preparation - a medicinal preparation that incorporates the substance is registered in the Register of Medicinal Preparations; The registration referred to in Section B is the first registration which enables use of the material in Israel for medical purposes;

PTE in Israel [The Israel Patents Law] Conditions for grant of an extension order (Unofficial Translation)   No extension order was granted previously in respect of the basic patent or in respect of the substance; If marketing approval has been granted in the United States of America – an extension order has also been granted for the reference patent in the United States of America, and it has not yet expired; If marketing approval has been granted in a recognized European country* – an extension order has also been granted for the reference patent in that country, and it has not yet expired; If marketing approvals have been granted in the United States of America and in at least one recognized European country – extension orders have also been granted for the reference patent in the United States of America and in that recognized European country, and they have not yet expired. *Recognized European Countries: i.e. Great Britain, Germany, Italy, France and Spain

PTE in Israel [The Israel Patents Law] Limitations   The total period of validity of the patent, including the PTE, will not be more than 25 years from the date on which the patent application is filed. The PTE will end no more than 14 years from the earliest date on which the pharmaceutical preparation which contains the substance was licensed in one of the Recognized Countries.

PTE in Israel – case law Appeal Case No. 41839-10-12 Tel-Aviv District Court The relevant section of the Israel Patents Law: 64D(e) If marketing approval has been granted in the United States of America – an extension order has also been granted for the reference patent in the United States of America, and it has not yet expired; The U.S. law which determines the period of protection which is granted to a patent changed during the period of time which is relevant to this case. The determining date for the change that occurred in U.S. law was June 8, 1995, two days after the day on which the U.S. patent application was filed – June 6, 1995.  

PTE in Israel – case law Appeal Case No. 41839-10-12 Tel-Aviv District Court The U.S. law set a de facto extension of patents, applications which were pending on June 8, 1995. The U.S. law stated that all of the patents, applications which were pending on June 8, 1995, would have a period of protection that is the greater of the twenty-year term from the day of the filing of the patent application or 17 years from the day on which the patent is granted. In the words of the law:   “All patents… that issued on an application that was filed before June 8, 1995, have a term that is the greater of the “twenty-year term” or seventeen years from the patent grant”. The U.S. Patent was granted on May 15, 2007. According to the U.S. law that was applicable on the day on which it was possible to request a patent term extension of the U.S. Patent, the term of the U.S. Patent was “extended” automatically, and the U.S. Patent is scheduled to expire only 17 years from the day on which the U.S. Patent was granted. In other words, on the day on which it was possible to request patent term extension of the U.S. Patent, the expiry date thereof was May 15, 2024.

PTE in Israel – case law Appeal Case No. 41839-10-12 Tel-Aviv District Court There was no dispute between the parties that the date on which the U.S. Patent will expire is later than the date on which the Israel Patent will expire, even if the term of the Israel Patent is extended to the maximum period permitted by law.   It is clear that in view of the above-mentioned provision of the U.S. law, there was no reason or basis for requesting a patent term extension of the U.S. Patent, since the term thereof had been “automatically extended” on the basis of the law which applied in the U.S. This “automatic” extension, which was set forth in the law, extended beyond the date regarding which it had been possible to extend the term of the U.S. Patent, via a patent term extension. The Intellectual Property Adjudicator who heard the case did not agree with this argument and refused to grant the requested extension. This appeal is currently pending before the District Court.